Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Long-term outcome for lymph node-positive prostate cancer

Prostate Cancer and Prostatic Diseases volume 11, pages 198–202 (2008)Cite this article

Abstract

Although the number of men with lymph node-positive prostate cancer has declined, it is still significant and the challenge remains on how best to treat these patients. Only long-term follow-up can give a true indication of the outcome in prostate cancer. We evaluated our experience in treating lymph node-positive prostate cancer with a median follow-up of 10.2 years. The overall 5-year survival was 78% and the 10-year survival was 56%. Length of tumor control depends on the type of treatment given. Adding androgen ablation improves the duration of control dramatically, although optimal timing is still uncertain.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Swanson GP, Basler J, Thompson IM . Current status of lymph node positive prostate cancer: incidence and predictors of outcome. Cancer 2006; 107: 439–450.

    Article  PubMed  Google Scholar 

  2. Swanson GP, Basler J, Thompson IM . Treatment options in lymph node positive prostate cancer. Cancer 2006; 106: 2531–2539.

    Article  PubMed  Google Scholar 

  3. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC . Management of stage D1 adenocarcinoma of the prostate: the John Hopkins experience 1974–1987. J Urol 1990; 144: 1425–1432.

    Article  CAS  PubMed  Google Scholar 

  4. Catalona WJ, Miller DR, Kavovssi LR . Intermediate term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 1988; 140: 540.

    Article  CAS  PubMed  Google Scholar 

  5. Cheng CWS, Bergstralh EJ, Zincke H . Stage D1 prostate cancer. Cancer 1993; 71: 996–1004.

    Article  CAS  PubMed  Google Scholar 

  6. Grimm MO, Kamphausen S, Hugenschmidt H, Stephan-Odenthal M, Ackermann R, Vogeli TA . Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen ablation. Eur Urol 2002; 41: 628–634.

    Article  PubMed  Google Scholar 

  7. Cadeddu JA, Partin AW, Epstein JI, Walsh PC . Stage D1 (T1-3,N1-3,M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 1997; 50: 251.

    Article  CAS  PubMed  Google Scholar 

  8. Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992; 70: 311.

    Article  CAS  PubMed  Google Scholar 

  9. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton Jr CE et al. Prognostic significance of lymph node metastases in prostate cancer. J Urol 1989; 142: 332.

    Article  CAS  PubMed  Google Scholar 

  10. Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adencarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 1997; 38: 931.

    Article  CAS  PubMed  Google Scholar 

  11. Puthawala AA, Syed AM, Austin PA, Cherlow JM, Perley JM, Shanberg AM et al. Long term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low-dose rate temporary iridium-192 interstitial implant and external beam radiotherapy. Cancer 2001; 92: 2084–2094.

    Article  CAS  PubMed  Google Scholar 

  12. Schmid HP, Mihatsch MJ, Hering F, Rutishauser G . Impact of minimal lymph node prognosis after radical prostatectomy. Eur Urol 1997; 31: 11–16.

    Article  CAS  PubMed  Google Scholar 

  13. Zagars GK, Pollack A, Eschenbach AC . Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 2001; 58: 233–239.

    Article  CAS  PubMed  Google Scholar 

  14. Aus G, Nordenskjold K, Robinson D, Rosell J, Varenhorst E . Prognostic factors and survival in node-positive (N1) prostate cancer – a prospective study based on data from a Swedish population-based cohort. Eur Urol 2003; 43: 627.

    Article  PubMed  Google Scholar 

  15. Schroeder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, Debois M et al. Early versus delayed endocrine treatment in pN1-3 M0 prostate cancer without local treatment of the primary tumor – results of EORTC 30846 – a phase II study. J Urol 2004; 172: 923–927.

    Article  Google Scholar 

  16. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D . Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. J Urol 2003; 169: 396, abstract no. 1480.

    Google Scholar 

  17. Da Pozzo LF, Cozzarini C, Bertini R, Colombo R, Mazzoccoli B, Roscigno M et al. Radical prostatectomy for node-positive prostate cancer: impact of adjuvant hormonal therapy and radiotherapy. J Urol 2003; 169: 494, abstract no. 1850.

    Google Scholar 

  18. Kramolowsky EV . The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988; 139: 1242–1244.

    Article  CAS  PubMed  Google Scholar 

  19. Keating NL, O'Malley AJ, Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448–4456.

    Article  CAS  PubMed  Google Scholar 

  20. Kumar RJ, Barqawi A, Crawford ED . Preventing and treating the complications of hormone therapy. Curr Urol Rep 2005; 6: 217–223.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Departments of Radiation Oncology and Urology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    G P Swanson

  2. Department of Mathematics, Abilene Christian University, Abilene, TX, USA

    M W Riggs

  3. Department of Urology, Scott and White Memorial Hospital and Clinic, Temple, TX, USA

    M Herman

Authors
  1. G P Swanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M W Riggs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G P Swanson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swanson, G., Riggs, M. & Herman, M. Long-term outcome for lymph node-positive prostate cancer. Prostate Cancer Prostatic Dis 11, 198–202 (2008). https://doi.org/10.1038/sj.pcan.4500983

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500983

Keywords

Search

Advanced search

Quick links